MetaVia Inc. Common Stock (MTVA)

• Market cap: $22.2M
• 1 day: -13.46%
• 5 days: 31.47%
• 1 month: 40.99%
• 3 months: 31.04%
• 6 months: -41.57%
• Year to date: -56.53%
• 1 year: -73.02%
• 5 years: -99.94%
• 10 years: -100%
• Sector: Healthcare
• Industry: Biotechnology

About: MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.

Employees: 8

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

400% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 1

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

7% more funds holding

Funds holding: 14 [Q1] → 15 (+1) [Q2]

6.87% less ownership

Funds ownership: 8.23% [Q1] → 1.36% (-6.87%) [Q2]

84% less capital invested

Capital invested by funds: $1.1M [Q1] → $171K (-$926K) [Q2]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $12
• Avg. target: $12
• High target: $12

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Andrew S. Fein

$12

Buy Assumed

4 Sep 2025